Sphingosine kinase 1 and cancer: a systematic review and meta-analysis.

<h4>Background</h4>Sphingosine kinase 1 (SK1) is a key regulator of the dynamic ceramide/sphingosine 1-phosphate rheostat balance and important in the pathological cancer genesis, progression, and metastasis processes. Many studies have demonstrated SK1 overexpressed in various cancers,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yun Zhang, Yan Wang, Zhi Wan, Shiping Liu, Yu Cao, Zhi Zeng
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/22d02978e8e94461ba0f365941c5a58d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:22d02978e8e94461ba0f365941c5a58d
record_format	dspace
spelling	oai:doaj.org-article:22d02978e8e94461ba0f365941c5a58d2021-11-18T08:30:37ZSphingosine kinase 1 and cancer: a systematic review and meta-analysis.1932-620310.1371/journal.pone.0090362https://doaj.org/article/22d02978e8e94461ba0f365941c5a58d2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24587339/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Sphingosine kinase 1 (SK1) is a key regulator of the dynamic ceramide/sphingosine 1-phosphate rheostat balance and important in the pathological cancer genesis, progression, and metastasis processes. Many studies have demonstrated SK1 overexpressed in various cancers, but no meta-analysis has evaluated the relationship between SK1 and various cancers.<h4>Methods</h4>We retrieved relevant articles from the PubMed, EBSCO, ISI, and OVID databases. A pooled odds ratio (OR) was used to assess the associations between SK1 expression and cancer; hazard ratios (HR) were used for 5-year and overall survival. Review Manager 5.0 was used for the meta-analysis, and publication bias was evaluated with STATA 12.0 (Egger's test).<h4>Results</h4>Thirty-four eligible studies (n=4,673 patients) were identified. SK1 positivity and high expression were significantly different between cancer, non-cancer, and benign tissues. SK1 mRNA and protein expression levels were elevated in the cancer tissues, compared with the normal tissues. SK1 positivity rates differed between various cancer types (lowest [27.3%] in estrogen receptor-positive breast cancer and highest [82.2%] in tongue squamous cell carcinoma). SK1 positivity and high expression were associated with 5-year survival; the HR was 1.86 (95% confidence interval [CI], 1.18-2.94) for breast cancer, 1.58 (1.08-2.31) for gastric cancer, and 2.68 (2.10-3.44) for other cancers; the total cancer HR was 2.21 (95% CI, 1.83-2.67; P < 0.00001). The overall survival HRs were 2.09 (95% CI, 1.35-3.22), 1.56 (1.08-2.25), and 2.62 (2.05-3.35) in breast, gastric, and other cancers, respectively. The total effect HR was 2.21 (95% CI, 1.83-2.66; P < 0.00001).<h4>Conclusions</h4>SK1 positivity and high expression were significantly associated with cancer and a shorter 5-year and overall survival. SK1 positivity rates vary tremendously among the cancer types. It is necessary to further explore whether SK1 might be a predictive biomarker of outcomes in cancer patients.Yun ZhangYan WangZhi WanShiping LiuYu CaoZhi ZengPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 2, p e90362 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yun Zhang Yan Wang Zhi Wan Shiping Liu Yu Cao Zhi Zeng Sphingosine kinase 1 and cancer: a systematic review and meta-analysis.
description	<h4>Background</h4>Sphingosine kinase 1 (SK1) is a key regulator of the dynamic ceramide/sphingosine 1-phosphate rheostat balance and important in the pathological cancer genesis, progression, and metastasis processes. Many studies have demonstrated SK1 overexpressed in various cancers, but no meta-analysis has evaluated the relationship between SK1 and various cancers.<h4>Methods</h4>We retrieved relevant articles from the PubMed, EBSCO, ISI, and OVID databases. A pooled odds ratio (OR) was used to assess the associations between SK1 expression and cancer; hazard ratios (HR) were used for 5-year and overall survival. Review Manager 5.0 was used for the meta-analysis, and publication bias was evaluated with STATA 12.0 (Egger's test).<h4>Results</h4>Thirty-four eligible studies (n=4,673 patients) were identified. SK1 positivity and high expression were significantly different between cancer, non-cancer, and benign tissues. SK1 mRNA and protein expression levels were elevated in the cancer tissues, compared with the normal tissues. SK1 positivity rates differed between various cancer types (lowest [27.3%] in estrogen receptor-positive breast cancer and highest [82.2%] in tongue squamous cell carcinoma). SK1 positivity and high expression were associated with 5-year survival; the HR was 1.86 (95% confidence interval [CI], 1.18-2.94) for breast cancer, 1.58 (1.08-2.31) for gastric cancer, and 2.68 (2.10-3.44) for other cancers; the total cancer HR was 2.21 (95% CI, 1.83-2.67; P < 0.00001). The overall survival HRs were 2.09 (95% CI, 1.35-3.22), 1.56 (1.08-2.25), and 2.62 (2.05-3.35) in breast, gastric, and other cancers, respectively. The total effect HR was 2.21 (95% CI, 1.83-2.66; P < 0.00001).<h4>Conclusions</h4>SK1 positivity and high expression were significantly associated with cancer and a shorter 5-year and overall survival. SK1 positivity rates vary tremendously among the cancer types. It is necessary to further explore whether SK1 might be a predictive biomarker of outcomes in cancer patients.
format	article
author	Yun Zhang Yan Wang Zhi Wan Shiping Liu Yu Cao Zhi Zeng
author_facet	Yun Zhang Yan Wang Zhi Wan Shiping Liu Yu Cao Zhi Zeng
author_sort	Yun Zhang
title	Sphingosine kinase 1 and cancer: a systematic review and meta-analysis.
title_short	Sphingosine kinase 1 and cancer: a systematic review and meta-analysis.
title_full	Sphingosine kinase 1 and cancer: a systematic review and meta-analysis.
title_fullStr	Sphingosine kinase 1 and cancer: a systematic review and meta-analysis.
title_full_unstemmed	Sphingosine kinase 1 and cancer: a systematic review and meta-analysis.
title_sort	sphingosine kinase 1 and cancer: a systematic review and meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/22d02978e8e94461ba0f365941c5a58d
work_keys_str_mv	AT yunzhang sphingosinekinase1andcancerasystematicreviewandmetaanalysis AT yanwang sphingosinekinase1andcancerasystematicreviewandmetaanalysis AT zhiwan sphingosinekinase1andcancerasystematicreviewandmetaanalysis AT shipingliu sphingosinekinase1andcancerasystematicreviewandmetaanalysis AT yucao sphingosinekinase1andcancerasystematicreviewandmetaanalysis AT zhizeng sphingosinekinase1andcancerasystematicreviewandmetaanalysis
_version_	1718421672054226944

Sphingosine kinase 1 and cancer: a systematic review and meta-analysis.

Ejemplares similares